Search results
21 sie 2018 · The USPSTF found convincing evidence that screening with cervical cytology alone, primary testing for high-risk HPV types (hrHPV testing) alone, or in combination at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer.
The USPSTF found poor evidence to determine whether new technologies, such as liquid-based cytology, computerized rescreening, and algorithm based screening, are more effective than conventional Pap smear screening in reducing incidence of or mortality from invasive cervical cancer.
21 sie 2018 · Screening with cervical cytology alone, primary testing for hrHPV alone, or both at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer. Clinicians should focus on ensuring that women receive adequate screening, appropriate evaluation of abnormal results, and indicated treatment, regardless of which ...
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
In 2018, the U.S. Preventive Services Task Force (USPSTF) recommended primary human papillomavirus (HPV) testing without cytology as an option for cervical cancer screening.
21 sie 2018 · The goal of screening for cervical cancer is to catch cervical cancer (or precancer) early; these cases are more treatable and curable than advanced cancer. There is good evidence that the Pap and HPV tests are good at finding cancer and precancerous cells.
Cervicovaginal HPV testing involves checking for the presence of 13 cancer-causing types of HPV in a collection of cells obtained from a swab of the cervix or vagina. HPV testing is approximately 90% accurate for detection of precancer.
